Industry News
Pharmaceutical Industry News

In challenging IRA price…
In challenging IRA price negotiations, Teva Pharmaceuticals has gained a partial win as the U.S. Court of Appeals for Washington, D.C., sent a previous ruling back to a lower court for further review. The challenge
Fierce editors break down Big…
Fierce editors break down Big Pharma’s second-quarter results, from AI and new leadership to the oral GLP-1 race and potential new blockbusters.
Valeris’ newly appointed chief…
Valeris' newly appointed chief strategy officer, Lauren Cole, comes from Merck subsidiary Verona Pharma, where she headed up patient services.
Biokin Pharma’s iza-bren, a…
Biokin Pharma’s iza-bren, a first-in-class antibody-drug conjugate partnered with Bristol Myers Squibb, has posted another positive phase 3 readout.
After a year of impairments,…
After a year of impairments, revenue downgrades and the ousting of its chief executive officer, Australian plasma and vaccine specialist CSL has flashed signs of recovery, projecting mid-single-digit growth in fiscal year 2027 for its
Revance has appointed Ulta Beauty…
Revance has appointed Ulta Beauty and Procter & Gamble alum Janelle Wichmann as its new chief marketing officer for skincare as it looks to boost commercial penetration of its Botox rival, Daxxify.
Regeneron’s Pasatru has crossed…
Regeneron's Pasatru has crossed the finish line with FDA approval after more than ten years of development. The drug is only the second approved treatment for FOP, an ultra-rare genetic condition that causes patients' soft
CMI Media Group has stepped up its…
CMI Media Group has stepped up its play for the orphan drug marketing sector, unveiling a framework tailored to the promotion of complex, low-incidence therapies.
After investors blanched last…
After investors blanched last month at a slower-than-expected launch timeline for Celcuity’s novel breast cancer med Revtorpyk, the company used much of its latest earnings call to address concerns over—and reaffirm confidence in—the pace of
Is Motion Sickness Preventable?
Experts say there are ways to stave off that dreaded queasy feeling.
Canada-based Eurofins CDMO Alphora…
Canada-based Eurofins CDMO Alphora boosted its development and production to meet growing demand for both non-potent and high-potency APIs.
The phase 3 misstep could undercut…
The phase 3 misstep could undercut EyePoint’s ambition to displace Eylea as the high-value treatment of choice for wAMD, a leading cause of blindness in adults over 50, while putting significant pressure on the identical
Quanovate voluntarily agreed to…
Quanovate voluntarily agreed to discontinue the marketing claims on its Mira fertility monitor and test wands that competitor Procter & Gamble had challenged before the BBB National Programs’ National Advertising Division.
In the first major workforce…
In the first major workforce reduction disclosed under new CEO Belén Garijo, Sanofi is laying off 229 employees from legacy Blueprint Medicines in Massachusetts as part of a post-acquisition integration.
Sandoz has collaborated with…
Sandoz has collaborated with Shanghai Henlius to gain commercialization rights to three biosimilars that are in early development. The deal is for Sandoz to pay up to $100.5 million up front for the initial assets
With its latest trial readout for…
With its latest trial readout for under-the-skin efgartigimod, argenx is adding another feather to the FcRn blocker’s cap.
AstraZeneca reported phase 3 lung…
AstraZeneca reported phase 3 lung cancer wins for Enhertu and a combination of Orpathys and Tagrisso, but the victories were eclipsed by the failure of its PD-1/CTLA-4 bispecific antibody in a simultaneous readout.
How One Woman With a Very Rare Disease Secured a Clinical Trial
Through sheer determination, Neena Nizar has become the first patient in a clinical trial testing a treatment for her disease — one so rare it affects just 30 people worldwide.
The pharmaceutical industry…
The pharmaceutical industry creates some of the most valuable products in human history: Medicines that can extend, save and better our lives. The product is rarely up for question, but the industry itself can struggle
Politicians and health group…
Politicians and health group leaders in Denmark are calling out Eli Lilly’s obesity awareness campaign in the country.


